Table 2

Patient-level biologic therapy history

Pt IDDiagnosisDisease historyAge at vedolizumab initiation (years)Follow-up duration since vedolizumab initiation (months)Previous adalimumab (yes/no)Previous infliximab (yes/no)Most recent anti-TNFDuration of anti-TNF (months)Type of loss of response to anti-TNF (primary or secondary)
1UCPancolitis UC since late 20161719NoYesInfliximab7Secondary
2CrohnIleocolonic Crohn’s disease since April 20131211YesYesAdalimumab17Secondary
3UCPancolitis UC since early 20111720YesYesAdalimumab10Secondary
4UCPancolitis since March 20101610YesYesAdalimumab4Secondary
5UCPancolitis since October 20151711NoYesInfliximab1Primary
6UCPancolitis UC since 2014187YesYesInfliximab8Secondary
7CrohnIleocolonic Crohn’s disease since July 20151116NoYesInfliximab6Secondary
8UCPancolitis UC since January 2012716NoYesInfliximab4Secondary
9UCIleocolonic Crohn’s disease since June 2016155NoYesInfliximab1Secondary
10UCPancolitis UC since August 2006219NoYesInfliximab10Secondary
11UCPancolitis UC since September 20151412NoYesInfliximab2Primary
12UCPancolitis UC since July 20131712NoYesInfliximab2Secondary
  • UC, ulcerative colitis; TNF, tumour necrosis factor,